microarray expression technology in clinical research of non-hodgkin lymphoma
Clicks: 241
ID: 165444
2007
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
81.0
/100
237 views
193 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Nowadays, in genomocentric era accelerated research of the human genome coupled with advances is enabling the comprehensive molecular profiling of human tissue. Particularly, DNA microarrays are powerful tools for obtaining global view of human non-Hodgkin lymphomas gene expression. Complex information from lymphomas "expression profiling" studies can, in turn, be used to create molecular markers that have diagnostic or prognostic implications. The gene "expression profiling" is not of routine clinical oncology practice, but is used in genomic classification of clinically relevant subgroups of non-Hodgkin lymphoma. The genomics biomarkers have been incorporated into current prognostic models which are based on IPI, R-IPI, and FLIPI. Molecular or pharmacogenomic profiling can be used as new therapeutic targets for patients who are refractory to current therapy. We discus the utility of DNA microarray-based lymphoma profiling in clinical oncology research, and identify future of research in lymphoma evolving fields.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (143 words).
Try re-searching for a better abstract.
| Reference Key |
vladimir2007archivemicroarray
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Baltić Vladimir;Baltić Milan |
| Journal | green energy and technology |
| Year | 2007 |
| DOI |
10.2298/AOO0702028B
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.